# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1 Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

### **SECTION 1. IDENTIFICATION**

Product name	:	FUZEON(R) Lyophilized Vials	(90 mg)
Product code	:	00010080811	
Manufacturer or supplier's of	deta	ails	
Company name of supplier	:	Genentech, Inc.	
Address	:	DNA Way 1 94080 South San Francisco CA USA	
Telephone E-mail address Emergency telephone	:	001-(650) 225-1000 info.sds@roche.com	
Emergency telephone num- ber	:	US Chemtrec phone	(800)-424-9300
Recommended use of the c	hen	nical and restrictions on use	
Recommended use	:	Formulated pharmaceutical ac	tive substance
Restrictions on use	:	For professional users only.	

## **SECTION 2. HAZARDS IDENTIFICATION**

GHS classification in accordance with 29 CFR 1910.1200				
Skin sensitization	:	Category 1		
GHS label elements				
Hazard pictograms	:			
Signal Word	:	Warning		
Hazard Statements	:	H317 May cause an allergic skin reaction.		
Precautionary Statements	:	<b>Prevention:</b> P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P272 Contaminated work clothing must not be allowed out of the workplace. P280 Wear protective gloves.		
		<b>Response:</b> P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.		

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1

Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

P363 Wash contaminated clothing before reuse.

#### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards

None known.

#### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Enfuvirtide	159519-65-0	78.3
D-Mannitol	69-65-8	19.6
Carbonic acid sodium salt (1:2)	497-19-8	2.1

#### SECTION 4. FIRST AID MEASURES

General advice	:	Move out of dangerous area. Show this material safety data sheet to the doctor in attendance. Do not leave the victim unattended.
If inhaled	:	Move to fresh air. If unconscious, place in recovery position and seek medical advice. If symptoms persist, call a physician.
In case of skin contact	:	If on skin, rinse well with water.
In case of eye contact	:	Flush eyes with water as a precaution. Remove contact lenses. Protect unharmed eye. Keep eye wide open while rinsing. If eye irritation persists, consult a specialist.
If swallowed	:	Keep respiratory tract clear. Do not give milk or alcoholic beverages. Never give anything by mouth to an unconscious person. If symptoms persist, call a physician.
Most important symptoms and effects, both acute and delayed	:	May cause an allergic skin reaction.
Notes to physician	:	The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

# FUZEON(R) Lyophilized Vials (90 mg)

Vers 1.1	ion	Revisio 02-06-2	·· -		Date of last issue: 06-10-2017 Date of first issue: 06-10-2017
	Suitable extinguishing	media	:		g measures that are appropriate to local ad the surrounding environment.
	Unsuitable extinguishii media	ng	:	High volume wate	er jet
	Specific hazards durin fighting	g fire	:	No information av	ailable.
	Hazardous combustior ucts	prod-	:	In case of fire has produced such as Ammonia Nitrogen oxides ( Carbon oxides Carbon monoxide Carbon dioxide (0 Sodium oxides	NOx)
	Further information		:	Use extinguishing	ure for chemical fires. I measures that are appropriate to local Ind the surrounding environment.
	Special protective equ for fire-fighters	ipment	:	Wear self-contair necessary.	ed breathing apparatus for firefighting if

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Avoid dust formation. Avoid breathing dust.
Environmental precautions	:	Prevent product from entering drains. Prevent further leakage or spillage if safe to do so. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Keep in suitable, closed containers for disposal.

#### SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion	:	Avoid dust formation. Provide appropriate exhaust ventilation at places where dust is formed.
Advice on safe handling	:	Avoid formation of respirable particles. Do not breathe vapors/dust. Avoid exposure - obtain special instructions before use. Avoid contact with skin and eyes. For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area. Dispose of rinse water in accordance with local and national regulations.

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1	1	Revision Date: 02-06-2020		Date of last issue: 06-10-2017 Date of first issue: 06-10-2017
			allergies, chronic	ble to skin sensitization problems or asthma, or recurrent respiratory disease should not ny process in which this mixture is being
C	onditions for safe sto	rage :	place. Electrical installat	ghtly closed in a dry and well-ventilated tions / working materials must comply with safety standards.
	urther information on ge conditions	stor- :	See label, packa	ge insert or internal guidelines
	urther information on ge stability	stor- :	No decomposition	n if stored and applied as directed.

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Enfuvirtide	159519-65-0	IOEL	1.5 mg/m3	Roche In- dustrial Hy- giene Com- mittee (RIHC)

Engineering measures

: No data available

### Personal protective equipment

Hand protection

Material	:	Protective gloves
Remarks Eye protection		Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly. Eye wash bottle with pure water Tightly fitting safety goggles
Skin and body protection	:	Choose body protection according to the amount and concentration of the dangerous substance at the work place.
Hygiene measures	:	When using do not eat or drink. When using do not smoke. Wash hands before breaks and at the end of workday.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Ap	pearance
' 'P	pourarioo

: lyophilized cake, sterile

# FUZEON(R) Lyophilized Vials (90 mg)

	evision Date: 2-06-2020	Date of last issue: 06-10-2017 Date of first issue: 06-10-2017
Color	: white, off-white	
Odor	: Not applicable	
Odor Threshold	: Not applicable	
рН	: Not applicable	
Melting point/range	: No data availab	le
Boiling point/boiling rang	e : No data availab	le
Flash point	: does not flash	
Evaporation rate	: No data availat	le
Self-ignition	: No data availat	le
Upper explosion limit / U flammability limit	oper : No data availab	le
Lower explosion limit / Lower explosion limit / Lo	ower : No data availab	le
Vapor pressure	: No data availat	le
Relative vapor density	: Not applicable	
Relative density	: No data availat	le
Solubility(ies) Water solubility	: No data availat	le
Solubility in other solv	rents : No data availat	le
Partition coefficient: n- octanol/water	: No data availab	le
Autoignition temperature	: No data availat	le
Decomposition temperat	ure : No data availat	le
Viscosity Viscosity, dynamic	: Not applicable	
Viscosity, kinematic	: Not applicable	

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	No decomposition if stored and applied as directed.

# FUZEON(R) Lyophilized Vials (90 mg)

Ver	sion
1.1	

Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

Conditions to avoid	:	Direct sources of heat.
Incompatible materials	:	Acids Bases Oxidizing agents
Hazardous decomposition products	:	No data available

#### SECTION 11. TOXICOLOGICAL INFORMATION

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: 3,141 mg/kg
		Method: Calculation method

#### Components:

#### Enfuvirtide:

Acute oral toxicity	:	LD50 Oral (Mouse): > 2,000 mg/kg Method: OECD Test Guideline 401

#### Skin corrosion/irritation

Not classified based on available information.

### Product: Remarks

: May cause skin irritation and/or dermatitis.

#### **Components:**

#### Enfuvirtide:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation
GLP	:	yes

### Serious eye damage/eye irritation

Not classified based on available information.

#### Product:

Remarks

: Product dust may be irritating to eyes, skin and respiratory system.

#### **Components:**

#### Enfuvirtide:

Species	: Rabbit
Method	: OECD Test Guideline 405
GLP	: yes
Remarks	: Mild eye irritation

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1 Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

#### Respiratory or skin sensitization

#### Skin sensitization

May cause an allergic skin reaction.

#### Respiratory sensitization

Not classified based on available information.

#### Product:

Remarks

: Causes sensitization.

#### **Components:**

#### Enfuvirtide:

Species Assessment Result	<ul><li>Guinea pig</li><li>May cause sensitization by skin contact</li><li>Causes sensitization.</li></ul>
Test Type	: Local lymph node assay (LLNA)
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative

### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

#### Enfuvirtide:

Genotoxicity in vitro	:	Result: negative Remarks: In vitro tests did not show mutagenic effects
Genotoxicity in vivo	:	Result: negative

#### Carcinogenicity

Not classified based on available information.

- **IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
- **OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.
- **NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### **Reproductive toxicity**

Not classified based on available information.

#### Components:

#### Enfuvirtide:

Effects on fetal development : Species: Rat

Application Route: s.c.

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1 Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

Dose: 30 mg/kg bw/day Result: No adverse effects.

### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### **Components:**

#### Enfuvirtide:

Species NOEL Application Route Exposure time	:	Rat 30 mg/kg s.c. 6 m
Species LD0 Application Route Exposure time	: : :	Rat 10 mg/kg i.v. 28 d

### Aspiration toxicity

Not classified based on available information.

#### **SECTION 12. ECOLOGICAL INFORMATION**

#### Ecotoxicity

### **Components:**

#### Enfuvirtide:

Toxicity to algae/aquatic : plants	EC50 (Selenastrum capricornutum (green algae)): > 100 mg/l Method: OECD Test Guideline 201 Remarks: nominal concentration
	NOErC (Selenastrum capricornutum (green algae)): 100 mg/l Method: OECD Test Guideline 201 Remarks: nominal concentration
	NOEyC (Selenastrum capricornutum (green algae)): 100 mg/l Method: OECD Test Guideline 201 Remarks: nominal concentration
Toxicity to microorganisms :	(activated sludge): 100 mg/l Exposure time: 14 d Method: OECD Test Guideline 301F Remarks: no adverse influence on substrate biodegradation
Ecotoxicology Assessment	

### Toxicity Data on Soil : Not expected to adsorb on soil.

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1		Revision 02-06-20		Date of last issue: 06-10-2017 Date of first issue: 06-10-2017
Other organisms relevant to : the environment			No data availabl	e
	Persistence and deg	radability		
	Components:			
	Enfuvirtide: Biodegradability	:	Biodegradation: Exposure time: 7 Method: OECD	
	BOD/COD	:	BOD: 1100 (BOI	D5)COD: 1490BOD/COD: 0.74 %
	Bioaccumulative pot	ential		
	Components:			
	Enfuvirtide: Partition coefficient: n- octanol/water	- :	Remarks: No da	ta available
	<b>Mobility in soil</b> No data available			
	Other adverse effect	S		
	Product: Ozone-Depletion Pote	ential :	tection of Stratos Substances Remarks: This p tured with a Clas	CFR Protection of Environment; Part 82 spheric Ozone - CAA Section 602 Class product neither contains, nor was manufa as I or Class II ODS as defined by the U ection 602 (40 CFR 82, Subpt. A, App.A

## SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	:	Do not contaminate ponds, waterways or ditches with chemical or used container. Send to a licensed waste management company. Can be disposed as waste water, when in compliance with local regulations.
Contaminated packaging	:	Empty remaining contents. Dispose of as unused product. Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1 Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

#### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code** Not applicable

Domestic regulation

**49 CFR** Not regulated as a dangerous good

#### **SECTION 15. REGULATORY INFORMATION**

#### EPCRA - Emergency Planning and Community Right-to-Know

#### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
SARA 311/312 Hazards	: Respiratory or skin	sensitization

#### Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

#### Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

FU	ZEON(R) Lyoph	ilized Vi	/ials (90 mg)					
Vers 1.1	ion	Revision [ 02-06-202						
	US State Regulations							
	Massachusetts Right To Know							
	Pennsylvania Right Enfuvirtide D-Mannitol	To Know	159519-65-0 69-65-8					
	Maine Chemicals of	High Conce	cern					
	Vermont Chemicals of High Concern							
	Washington Chemicals of High Concern							
	The ingredients of the DSL	nis product :	t are reported in the following inventories: This product contains the following components that are not on the Canadian DSL nor NDSL.					
			Enfuvirtide					
	AICS	:	Not in compliance with the inventory					
	NZIoC	:	Not in compliance with the inventory					
	ENCS	:	Not in compliance with the inventory					
	ISHL	:	Not in compliance with the inventory					
	KECI	:	Not in compliance with the inventory					
	PICCS	:	Not in compliance with the inventory					
	IECSC	:	Not in compliance with the inventory					
	TCSI	:	Not in compliance with the inventory					
	TSCA	:	Substance(s) not listed on TSCA inventory					

#### **TSCA** list


No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

## SECTION 16. OTHER INFORMATION


# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1 Revision Date: 02-06-2020



Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Revision Date** 

02-06-2020

# FUZEON(R) Lyophilized Vials (90 mg)

Version 1.1 Revision Date: 02-06-2020

Date of last issue: 06-10-2017 Date of first issue: 06-10-2017

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810